BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260424T090000
DTEND;TZID=Europe/Stockholm:20260424T100000
DTSTAMP:20260527T140900
CREATED:20260408T171107Z
LAST-MODIFIED:20260424T070435Z
UID:10001799-1777021200-1777024800@www.scilifelab.se
SUMMARY:Clinical and translational analyses in the neoadjuvant PREDIX trials in breast cancer
DESCRIPTION:Speaker\n\n\n\nTheodoros Foukakis\, Karolinska Institutet \n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nAbstract\n\n\n\nThe PREDIX trials are academic\, randomised phase 2 studies of neoadjuvant therapy in breast cancer\, coordinated by Karolinska. Patients with luminal breast cancer were randomised to either chemotherapy or endocrine therapy in combination with palbociclib. Patients with HER2-positive disease received preoperatively either a standard of care combination of chemotherapy and HER2-targeting antibodies or the antibody-drug conjugate trastuzumab-emtansine. Both trials had a translational focus with serial biopsies and blood samples collected at baseline and during treatment. A comprehensive multimodal profiling of the tumours has been carried out\, and the molecular profiles of the tumours have been correlated to the clinical outcomes. The initial results from these studies will be presented. \n\n\n\nShort biography\n\n\n\nTheodoros Foukakis\, MD\, PhD\, is Professor of Oncology at Karolinska Institutet and a senior attending physician and scientific head for breast cancer at the Comprehensive Cancer Centre\, Karolinska University Hospital\, Stockholm\, Sweden. He is head of the national guidelines group for breast cancer in Sweden\, a member of the Swedish Breast Cancer Group (SweBCG)\, and a steering committee member of The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). \n\n\n\nDr Foukakis completed his medical studies at the University of Crete\, Greece\, in 2002 and moved to Stockholm\, Sweden\, where he pursued a PhD in cancer genetics at Karolinska Institutet. Subsequently\, he undertook clinical training in Oncology at Karolinska University Hospital between 2005 and 2009 and has since worked as a specialist\, combining clinical work with research\, with a focus on breast cancer. \n\n\n\nHe has led several investigator-initiated trials sponsored by Karolinska University Hospital and served as national principal investigator for many industry-sponsored trials from phase 1 to phase 3. \n\n\n\nHe leads a research group of 22 members and has secured independent funding through national or international competitions over the last 10 years. His group is particularly interested in drug and biomarker development in breast cancer with a focus on multi-omics analyses and machine learning. \n\n\n\nAbout Clinical Talk:\n\n\n\nAfter seven successful seasons and over seventy dedicated speakers\, we are excited to continue showcasing the contributions of our diverse clinical\, academic\, and industry life science community. This season will feature ten insightful talks following our well-established format. \n\n\n\nThe overarching theme is “How to Achieve Feasible Implementation.” Sessions will be held monthly on Fridays from 09:00 a.m. to 10:00 a.m. via Zoom\, with occasional exceptions. Each talk will be followed by an engaging Q&A session\, moderated by the standing host\, Rikard Fred\, and a guest moderator with subject-matter expertise to enrich the discussion. \n\n\n\nIn today’s post-pandemic world\, let’s explore how academic\, clinical\, and industry research\, together with technological advances\, can drive practical\, sustainable solutions. Join us for an opportunity to gain fresh insights\, expand your knowledge\, and connect with experts shaping the future of life sciences! \n\n\n\nClinical talks are organised by SciLifeLab.
URL:https://www.scilifelab.se/event/clinical-talk-clinical-and-translational-analyses-in-the-neoadjuvant-predix-trials-in-breast-cancer-biological-insights-and-clinical-implications/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260327T150000
DTEND;TZID=Europe/Stockholm:20260327T160000
DTSTAMP:20260527T140900
CREATED:20260128T070949Z
LAST-MODIFIED:20260206T071346Z
UID:10001736-1774623600-1774627200@www.scilifelab.se
SUMMARY:The Silent Crisis in Oncology Real-World Evidence — and How to Fix It
DESCRIPTION:Asieh Golozar\, founder and CEO of Nemesis Health \n\n\n\nThe programme includes a 40-minute talk followed by a 20-minute Q&A session \n\n\n\n\n\n\n\nBiography\n\n\n\nAsieh Golozar is the founder and CEO of Nemesis Health\, a company dedicated to progressing cancer research through large scale real-world evidence from a network of cancer centers. She is a physician-epidemiologist and biostatistician with more than 20 years of experience in real-world evidence generation\, observational research and evaluation of healthcare interventions within government\, academia\, and industry.  \n\n\n\nAsieh holds a PhD in Epidemiology from the Johns Hopkins University and a Master of Health Sciences in Biostatistics from Johns Hopkins University School of Public Health\, supported by a postdoctoral research fellowship award with the National Cancer Institute’s Division of Cancer Epidemiology and Genetics. She earned her medical degree from Tehran University of Medical Sciences. \n\n\n\nAfter her education\, she joined the faculty at the Johns Hopkins University Department of Epidemiology\, where she focused on cancer and diabetes epidemiology\, the application of epidemiologic and statistical methods for robust synthesis of evidence from epidemiologic data and applying evidence-based findings to strengthen public heath infrastructure and policies. She then transitioned into industry roles at Bayer AG\, AstraZeneca\, and Regeneron\, where she led lifecycle management and real-world evidence generation activities in oncology\, women’s health\, and other therapeutic areas.  \n\n\n\nCurrently\, Golozar holds the position of professor of the practice at Northeastern University\, where she is engaged in epidemiological methodology and statistics for real-world evidence. She holds faculty appointments at Johns Hopkins University in the Department of Epidemiology and the Division of GeneralInternal Medicine at the School of Medicine. Additionally\, she is the leader of the Oncology Working Group at OHDSI\, a global open source and open science collaborative. \n\n\n\nAbstract\n\n\n\nHigh-quality real-world evidence (RWE) in oncology requires detailed clinical data\, standardized representations of tumor characteristics\, and analytic methods that can be reproduced across institutions and health systems. Most oncology datasets remain fragmented\, differ in structure\, and lack the granularity needed to study treatment patterns\, biomarker-driven care\, disease trajectories\, and outcomes at scale. The OMOP Common Data Model\, together with oncology-specific conventions\, provides a harmonized framework for representing diagnoses\, histology\, stage\, biomarkers\, treatments\, and outcomes in a way that supports transparent and reproducible analytics. \n\n\n\nFALCON (Federated Alliance for Large-Scale Oncology Research) is a growing international network built on this foundation. It enables federated studies using shared methods while keeping data securely within each institution. Early applications of this approach have demonstrated its ability to characterize real-world treatment patterns\, evaluate guideline relevance\, study disease progression\, and support methodological development across diverse populations and health-care environments. \n\n\n\nThis talk will present the scientific foundations\, methodological considerations\, and early results demonstrating how standardized data and federated analytics can advance oncology RWE. The work highlights opportunities for deeper collaboration across pathology\, oncology\, genomics\, and data science to build scalable\, trustworthy real-world evidence for cancer research. \n\n\n\nRegistration\n\n\n\nAbout Clinical Talks\n\n\n\nClinical Talks returns with a new season! \n\n\n\nAfter seven successful seasons and over seventy dedicated speakers\, we are excited to continue showcasing the contributions of our diverse clinical\, academic\, and industry life science community. This season will feature ten insightful talks following our well-established format. \n\n\n\nThe overarching theme is “How to Achieve Feasible Implementation.” Sessions are held monthly \,usually on Fridays via Zoom\, with occasional exceptions. Each talk will be followed by an engaging Q&A session\, moderated by standing host Rikard Fred and a guest moderator with subject matter expertise to enrich the discussion. \n\n\n\nIn today’s rapidly evolving post-pandemic landscape\, exploring how academic\, clinical\, and industry research\, combined with technological advancements\, can drive practical and sustainable solutions is crucial. Join us for an opportunity to gain fresh insights\, expand your knowledge\, and connect with experts shaping the future of life sciences! \n\n\n\nClinical Talks are organised by SciLifeLab.
URL:https://www.scilifelab.se/event/the-silent-crisis-in-oncology-real-world-evidence-and-how-to-fix-it/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260227T090000
DTEND;TZID=Europe/Stockholm:20260227T094000
DTSTAMP:20260527T140900
CREATED:20260123T100627Z
LAST-MODIFIED:20260206T071105Z
UID:10001732-1772182800-1772185200@www.scilifelab.se
SUMMARY:FOCU.SE  - The Swedish national collaborative group for the implementation of comprehensive genetic profiling in patients with advanced cancer
DESCRIPTION:The programme includes a 40-minute talk followed by a 20-minute Q&A session \n\n\n\nBiography\n\n\n\nEdvard Abel\, MD\, PhD\, is a consultant in oncology at the Dep of Oncology at Sahlgrenska Comprehensive Cancer Center in Gothenburg. He holds the position of Centre Director at Sahlgrenska CCC\, as well as Medical Lead of the Phase I/First-in-Human trial unit at the Dep of Oncology. Dr Abel is the clinical principal investigator of the coming FOCU.SE trial\, a national collaboration between Genomic Medicine Sweden\, SciLifeLab and the oncological trial units\, among others.  \n\n\n\n\n\n\n\nAbstract\n\n\n\nThe FOCU.SE trial platform provides a nationwide clinical infrastructure for the implementation of PCM in Sweden. By enabling biomarker-guided use of approved drugs within a structured clinical trial framework and supporting systematic evaluation of clinical outcomes\, the platform aims to accelerate equitable access to personalised cancer therapy across healthcare regions. In parallel\, it generates high-quality real-world evidence to support regulatory decision-making and potential expansion of indications for targeted therapies \n\n\n\nAbout Clinical Talk\n\n\n\nClinical Talks returns with a new season! \n\n\n\nAfter seven successful seasons and over seventy dedicated speakers\, we are excited to continue showcasing the contributions of our diverse clinical\, academic\, and industry life science community. This season will feature ten insightful talks following our well-established format. \n\n\n\nThe overarching theme is “How to Achieve Feasible Implementation.” Sessions are held monthly \,usually on Fridays via Zoom\, with occasional exceptions. Each talk will be followed by an engaging Q&A session\, moderated by standing host Rikard Fred and a guest moderator with subject matter expertise to enrich the discussion. \n\n\n\nIn today’s rapidly evolving post-pandemic landscape\, exploring how academic\, clinical\, and industry research\, combined with technological advancements\, can drive practical and sustainable solutions is crucial. Join us for an opportunity to gain fresh insights\, expand your knowledge\, and connect with experts shaping the future of life sciences! \n\n\n\nClinical Talks are organised by SciLifeLab. \n\n\n\nLink to Registration
URL:https://www.scilifelab.se/event/focu-se-the-swedish-national-collaborative-group-for-the-implementation-of-comprehensive-genetic-profiling-in-patients-with-advanced-cancer/
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20251128T090000
DTEND;TZID=Europe/Stockholm:20251128T093000
DTSTAMP:20260527T140900
CREATED:20251117T152805Z
LAST-MODIFIED:20251127T042951Z
UID:10001666-1764320400-1764322200@www.scilifelab.se
SUMMARY:Multimodal explorative testing in the ON-OFF ibrutinib trial in CLL
DESCRIPTION:Multimodal explorative testing in the ON-OFF ibrutinib trial in CLLRichard Rosenquist Brandell\, Karolinska Institutet & Karolinska University Hospital \n\n\n\nChronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western World and displays substantial variability in clinical course\, ranging from indolent disease requiring no therapy to highly aggressive forms with short survival despite treatment. Although the past decade has seen major advances in drug development\, CLL remains incurable. Targeted therapies\, particularly Bruton’s tyrosine kinase inhibitors (BTKi)\, have become central to CLL management. However\, continuous long-term BTKi administration\, such as with ibrutinib\, is associated with considerable significant side-effects\, including cardiac arrhythmias. Furthermore\, despite its proven efficacy in both treatment-naïve and relapsed/refractory CLL\, resistance to ibrutinib continues to challenge durable disease control. To address these limitations\, we conducted a phase 1b/2 prospective\, single-arm\, multicenter study evaluating controlled treatment cessation as a strategy to preserve tolerability and maintain sensitivity to ibrutinib\, while also improving cost-effectiveness. The study protocol incorporated serial blood sampling prior to treatment initiation and throughout on/off treatment periods. Here\, we leverage this unique longitudinal sample collection to perform multimodal profiling\, including genomic and transcriptomic sequencing as well as proteomics\, to investigate mechanisms of drug response and resistance. We provide an update on the current status of the study and ongoing analyses. \n\n\n\nregistration\n\n\n\nBiography \n\n\n\n\n\n\n\nRichard Rosenquist Brandell is Professor of Clinical Genetics at the Department of Molecular Medicine and Surgery\, Karolinska Institutet\, and Senior Physician in Clinical Genetics at Karolinska University Hospital\, Sweden. Focusing on hematological malignancies and utilizing high-throughput sequencing and other innovative technologies\, his research team has identified novel prognostic and predictive biomarkers that have refined disease classification and significantly improved patient risk-stratification and clinical decision-making. Richard Rosenquist Brandell initiated and led the Clinical Genomics Unit within Science for Life Laboratory (SciLifeLab) in Uppsala (2013-2017) and was platform director for the Clinical Genomics platform (2016-2021) within SciLifeLab\, which includes seven Clinical Genomics units across Sweden. He is currently Director of Genomic Medicine Sweden (GMS)\, a national infrastructure for implementation of precision medicine. Rosenquist Brandell is a member of the Nobel Assembly at Karolinska Institutet.
URL:https://www.scilifelab.se/event/multimodal-explorative-testing-in-the-on-off-ibrutinib-trial-in-cll/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250902T160000
DTEND;TZID=Europe/Stockholm:20250902T170000
DTSTAMP:20260527T140900
CREATED:20250827T110117Z
LAST-MODIFIED:20250827T154412Z
UID:10001592-1756828800-1756832400@www.scilifelab.se
SUMMARY:OMOP as a standard for analytics\, generating real-world evidence\, and federated machine learning
DESCRIPTION:Eric Fey\, Development Manager AI at Helsinki University Hospital \n\n\n\nAbstract\n\n\n\nIn the rapidly evolving landscape of healthcare data analytics\, the OMOP Common Data Model (CDM) has emerged as a game-changer\, revolutionizing the way real-world evidence (RWE) is generated and utilized. The presentation will draw from the OMOP experience from Helsinki University Hospital (HUS) and outline key steps\, required competencies\, and infrastructure needed for implementation\, as well as information on how to join and leverage the international OHDSI network in the process. The presentation will show how HUS has successfully navigated the process from data sources\, through ETL (Extract\, Transform\, Load) to OMOP data\, quality control\, to the first federated real-world study\, and further into swarm-learning for predictive modelling in precision medicine. Use cases covered will include participation in DARWIN\, an international OMOP study on immune checkpoint inhibitor uptake in metastatic non-small cell lung cancer (iCAN mNSCLC study-a-thon)\, and a swarm learning study across the Finnish university hospitals to cooperatively build a predictive model in acute myeloid leukaemia (AML). \n\n\n\n \n\n\n\n \n\n\n\n\n \n\n\n\nBiography\n\n\n\nEric Fey\, PhD\, MEng is a distinguished scientists in systems biology and medicine\, currently spearheading the development of AI applications and federated learning at the Helsinki University Hospital. His roles include the Data Team Lead at the iCAN Digital Precision Cancer Medicine flagship\, University of Helsinki; AI Development Manager\, HUS Helsinki University Hospital; and National Node Lead\, OHDSI Finland. With a PhD in Engineering and a strong background in system biology and data science\, Eric has a proven track record in academia\, entrepreneurship\, and industry\, including the 2017 Irish Laboratory Award for Collaboration Achievement\, and a significant role as Assistant Professor at University College Dublin School of Medicine. His innovative work in establishing the swarm-learning capabilities across the Finnish university hospitals and a published proof-of-concept that mathematical models of cancer signalling can outperform classical biochemical biomarkers demonstrate his commitment to advancing precision medicine through technology. \n\n\n\n\n\n\n\n\nRegistration\n\n\n\nPlease register\, the Confirmation email provides a Zoom link to the online event. \n\n\n\nRegister\n\n\n\nAbout Clinical Talks\n\n\n\nClinical Talks returns with a new season! \n\n\n\nAfter seven successful seasons and over seventy dedicated speakers\, we are excited to continue showcasing the contributions of our diverse clinical\, academic\, and industry life science community. This season will feature ten insightful talks following our well-established format. The overarching theme is “How to Achieve Feasible Implementation.”  \n\n\n\nSessions will be held monthly on Fridays from 09:00 a.m. to 09:30 a.m. via Zoom\, with occasional exceptions. Each talk will be followed by an engaging Q&A session\, moderated by standing host Rikard Fred and a guest moderator with subject matter expertise to enrich the discussion.  \n\n\n\nIn today’s rapidly evolving post-pandemic landscape\, exploring how academic\, clinical\, and industry research\, combined with technological advancements\, can drive practical and sustainable solutions is crucial.  \n\n\n\nJoin us for an opportunity to gain fresh insights\, expand your knowledge\, and connect with experts shaping the future of life sciences! \n\n\n\nThe SciLifeLab’s Precision Medicine Capability organises Clinical Talks.
URL:https://www.scilifelab.se/event/omop-as-a-standard-for-analytics-generating-real-world-evidence-and-federated-machine-learning/
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2024/01/Clinical-Talks-sq.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250523T090000
DTEND;TZID=Europe/Stockholm:20250523T100000
DTSTAMP:20260527T140900
CREATED:20250514T044404Z
LAST-MODIFIED:20250516T131448Z
UID:10001549-1747990800-1747994400@www.scilifelab.se
SUMMARY:From Algorithms to the Clinic: How we are bringing digital technologies into clinical practice
DESCRIPTION:Marco Perez\, an Associate Professor at Stanford University \n\n\n\nBiography\n\n\n\nDr. Marco Perez\, an Associate Professor at Stanford University\, focuses on understanding the causes of cardiovascular disease and the role of digital health technologies in improving cardiovascular health. He has been involved in landmark studies\, including the Women’s Health Initiative and the Apple Heart Study\, which validated smartwatch detection of atrial fibrillation. Currently\, he serves as the Principal Investigator of the Central Coordinating Centre for the REACT-AF clinical trial\, which explores a “pill-in-the-pocket” anticoagulation approach for atrial fibrillation using smartwatches.  \n\n\n\n\n\n\n\nAbstract\n\n\n\nThe availability of digital tools in medicine is expanding rapidly. More than ever before\, we have access to large datasets and machine learning tools that can help us decipher this data. In addition\, our patients are being monitored nearly continuously with consumer devices that are connected and available to us as a tool for research and health care delivery. We will discuss our experience with how we are using these tools in clinical trials\, what we can learn from these studies and where we need to go next to make the most significant impact. \n\n\n\nAbout Clinical Talks\n\n\n\nClinical Talks returns with a new season! \n\n\n\nAfter seven successful seasons and over seventy dedicated speakers\, we are excited to continue showcasing the contributions of our diverse clinical\, academic\, and industry life science community. This season will feature ten insightful talks following our well-established format. \n\n\n\nThe overarching theme is “How to Achieve Feasible Implementation.” Sessions will be heldmonthly on Fridays from 09:00 a.m. to 09:30 a.m. via Zoom\, with occasional exceptions. Each talk will be followed by an engaging Q&A session\, moderated by standing host Rikard Fred and a guest moderator with subject matter expertise to enrich the discussion. \n\n\n\nIn today’s rapidly evolving post-pandemic landscape\, exploring how academic\, clinical\, and industry research\, combined with technological advancements\, can drive practical and sustainable solutions is crucial. Join us for an opportunity to gain fresh insights\, expand your knowledge\, and connect with experts shaping the future of Life Sciences! \n\n\n\nClinical Talks are organised by SciLifeLab. \n\n\n\nRegister Here\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n“From Algorithms to the Clinic: How we are bringing digital technologies into clinical practice”
URL:https://www.scilifelab.se/event/from-algorithms-to-the-clinic-how-we-are-bringing-digital-technologies-into-clinical-practice/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250425T090000
DTEND;TZID=Europe/Stockholm:20250425T094000
DTSTAMP:20260527T140900
CREATED:20250408T075501Z
LAST-MODIFIED:20250408T114952Z
UID:10001524-1745571600-1745574000@www.scilifelab.se
SUMMARY:Locoregional cancer therapies for uveal melanoma.
DESCRIPTION:Speaker: Roger Olofsson Bagge\, Professor och Överläkare \n\n\n\nAvdelningen för Kirurgi\, Institutionen för kliniska vetenskaper\, Sahlgrenska Akademin\, Göteborgs Universitet\, Sektionen för Bröst och Melanomkirurgi\, Kirurgi\, Sahlgrenska Universitetssjukhuset \n\n\n\nAbstract \n\n\n\nUveal melanoma is a cancer arising from the eye. Prognosis is poor in that patients often develop liver metastases and no effective treatments are currently available. Our recent phase III randomized trial (SCANDIUM) demonstrated the effectiveness of locoregional treatment with isolated hepatic perfusion (IHP) while our translational research suggests that this treatment can activate the immune system. By sensitizing uveal melanoma to immunotherapy\, efficacy of treatment may be further increased as we showed by combining IHP with modern immunotherapy (SCANDIUM-II). \n\n\n\nThe purpose of this randomized clinical trial\, the SCANDIUM-III trial\, is to further explore treatment efficacy with a novel clinical trial combining a locoregional cancer treatment with modern immunotherapy. The specific aim is to evaluate if the combination of minimal-invasive percutaneous hepatic perfusion together with the checkpoint inhibitors ipilimumab and nivolumab can improve response rate and survival. Patients will be included from all regions of Sweden\, and if achieving clinically significant findings from the trial the procedure will likely be incorporated into clinical practice without major delays. \n\n\n\nA major limitation is that we currently lack predictive and prognostic factors. We therefore aim to perform a multimodal precision medicine approach using ctDNA\, proteomics\, metabolomics as well as immuneprofiling in both existing samples (SCANDIUM and SCANDIUM-II) as well as prospectively in the SCANDIUM-III trial\, aiming at correlating multimodal liquid biopsies with tumor response\, progression and survival. \n\n\n\nPatients\, clinical samples\, infrastructure and other resources needed for the project are available through the participating University hospital sites and Comprehensive Cancer Center structures. We use the research infrastructure Clinical Studies Sweden – Gothia Forum for clinical trial support\, Biobank Sweden for biobanking and SciLifeLab for our planned multimodal analysis. \n\n\n\nregistration\n\n\n\nAbout Clinical Talks \n\n\n\nAfter seven successful seasons and over seventy dedicated speakers\, we are excited to continue showcasing the contributions of our diverse clinical\, academic\, and industry Life Science community. This season will feature ten insightful talks following our well-established format. \n\n\n\nThe overarching theme is “How to Achieve Feasible Implementation.” Sessions will be held monthly on Fridays from 09:00 to 09:30 a.m. via Zoom\, with occasional exceptions. Each talk will be followed by an engaging Q&A session\, moderated by standing host Rikard Fred and a guest moderator with subject matter expertise to enrich the discussion. \n\n\n\nIn today’s rapidly evolving post-pandemic landscape\, exploring how academic\, clinical\, and industry research—combined with technological advancements—can drive practical and sustainable solutions is crucial. Join us for an opportunity to gain fresh insights\, expand your knowledge\, and connect with experts shaping the future of Life Sciences!
URL:https://www.scilifelab.se/event/locoregional-cancer-therapies-for-uveal-melanoma/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250321T090000
DTEND;TZID=Europe/Stockholm:20250321T094000
DTSTAMP:20260527T140900
CREATED:20250221T143110Z
LAST-MODIFIED:20250227T154106Z
UID:10001494-1742547600-1742550000@www.scilifelab.se
SUMMARY:Precision phenotyping in dilated cardiomyopathy
DESCRIPTION:Charlotta Ljungman\, Senior consultant \n\n\n\nThis Clinical talks has been rescheduled – from February 28 to March 21. Any prior registrations remains valid. \n\n\n\nCharlotta Ljungman is senior consultant and associate professor in cardiology working at Sahlgrenska University Gothenburg. \n\n\n\n\n\n\n\nHer research involves aspects of heart failure and cardiomyopathy and she is the founder of Sahlgrenska Cardiomyopathy Center. She is also the chair of the Swedish heart failure registry (Swede-HF) \n\n\n\nregister to receive zoom link\n\n\n\nAbstract \n\n\n\nPrecision phenotyping has been suggested to find new subtypes and biomarkers in heart failure and dilated cardiomyopathy (DCM)\, the most common cardiomyopathy\, and were the cause in 50% of the cases is unknown. Therefore\, the aim of this project is to combine proteomics and metabolomics to: \n\n\n\n\nUnderstand cardiac energy metabolism in heart failure and DCM.\n\n\n\nFind subtypes and biomarkers by multimodal precision phenotyping with proteomics and integration of data\n\n\n\n\nOnce established\, the precision phenotyping approach may allow identification of patients/subtypes at greatest risk\, find new biomarkers and allow intervention and personalized follow-up of high-risk individuals.  \n\n\n\nThe aim will be achieved by investigating cardiac energy metabolism (uptake and release) and proteomic profile in relation to cardiac function at rest and during exercise\, in patients in comparison to healthy controls.  Patients undergoing right heart catheterization (RHC) with the diagnosis of heart failure and DCM without metabolic disease are included in a prospective mechanistic case control study of cardiac energetics; the MEtabolic CHAracterization of patients with Dilated cardiomyopathy (MECHAD) study. Age and sex matched controls without heart failure undergoing electrophysiological examination are included. Arterial blood supply tissues and organs with oxygen and metabolites for energy and venous blood carry the metabolic by-products and carbon oxide from tissues and organs. This allows to calculate uptake and release of metabolites and oxygen through arteriovenous approach by simultaneous sampling in artery (to the heart) and the coronary sinus (from the heart) when performing RHC and calculate cardiac energy metabolism and collect samples for proteomics profiling. Patients undergo clinical examinations including medical history\, alcohol use disorders identification test\, Kansas City Cardiomyopathy Questionnaire\, ECG\, blood pressure\, Transthoracical echocardiography (TTE) and Cardiopulmonary exercise testing (CPET). All patients are followed for 12 months. \n\n\n\nClinical Talks returns with a new season! \n\n\n\nAfter seven successful seasons and over seventy dedicated speakers\, we are excited to continue showcasing the contributions of our diverse clinical\, academic\, and industry Life Science community. This season will feature ten insightful talks\, following our well-established format. \n\n\n\nThe overarching theme is “How to Achieve Feasible Implementation.” Sessions will be held monthly on Fridays from 09:00 to 09:30 am via Zoom\, with occasional exceptions. Each talk will be followed by an engaging Q&A session\, moderated by standing host Rikard Fred\, alongside a guest moderator with subject matter expertise to enrich the discussion. \n\n\n\nIn today’s rapidly evolving post-pandemic landscape\, it is crucial to explore how academic\, clinical\, and industry research—combined with technological advancements—can drive practical and sustainable solutions. Join us for an opportunity to gain fresh insights\, expand your knowledge\, and connect with experts shaping the future of Life Sciences! \n\n\n\nClinical Talks are organized by the SciLifeLab’s Precision Medicine Capability
URL:https://www.scilifelab.se/event/precision-phenotyping-in-dilated-cardiomyopathy/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240524T090000
DTEND;TZID=Europe/Stockholm:20240524T093000
DTSTAMP:20260527T140900
CREATED:20240130T123401Z
LAST-MODIFIED:20240311T091702Z
UID:10001132-1716541200-1716543000@www.scilifelab.se
SUMMARY:To solve the unsolved and phenotype the solved rare diseases
DESCRIPTION:Ann Nordgren\, Karolinska Institutet \n\n\n\n \n\n\n\nregistration\n\n\n\nClinical Talks \n\n\n\nClinical Talks is an educational seminar series open to everyone. It is organized by the SciLifeLab Precision Medicine Capability\, and invites a mixture of speakers that are experts with a clinical perspective on topics concerning rare diseases\, cancer\, microbiology and bioinformatics. \n\n\n\nHealth is individual and patients can benefit greatly from personalized treatments\, tailored for their specific molecular disposition. This rapidly emerging field\, known as Precision Medicine\, relies on technology development and requires close collaboration between scientists and healthcare professionals. SciLifeLab aims to bring cutting-edge technologies\, first-class expertise and data infrastructure to build the foundation of tomorrow’s Precision Medicine.
URL:https://www.scilifelab.se/event/rare-diseases/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2024/01/Clinical-Talks-sq.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240502T090000
DTEND;TZID=Europe/Stockholm:20240502T093000
DTSTAMP:20260527T140900
CREATED:20240130T122610Z
LAST-MODIFIED:20240502T063112Z
UID:10001131-1714640400-1714642200@www.scilifelab.se
SUMMARY:Cancelled: The role of diagnostics in precision cancer medicine
DESCRIPTION:This event has been cancelled. We apologize for the inconvenience. \n\n\n\n \n\n\n\n \n\n\n\nClinical Talks \n\n\n\nClinical Talks is an educational seminar series open to everyone. It is organized by the SciLifeLab Precision Medicine Capability\, and invites a mixture of speakers that are experts with a clinical perspective on topics concerning rare diseases\, cancer\, microbiology and bioinformatics. \n\n\n\nHealth is individual and patients can benefit greatly from personalized treatments\, tailored for their specific molecular disposition. This rapidly emerging field\, known as Precision Medicine\, relies on technology development and requires close collaboration between scientists and healthcare professionals. SciLifeLab aims to bring cutting-edge technologies\, first-class expertise and data infrastructure to build the foundation of tomorrow’s Precision Medicine.
URL:https://www.scilifelab.se/event/the-role-of-diagnostics-in-precision-cancer-medicine/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2024/01/Clinical-Talks-sq.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240308T090000
DTEND;TZID=Europe/Stockholm:20240308T093000
DTSTAMP:20260527T140900
CREATED:20240130T122207Z
LAST-MODIFIED:20240130T122316Z
UID:10001130-1709888400-1709890200@www.scilifelab.se
SUMMARY:Systems genomics for population health: From risk prediction to aetiology
DESCRIPTION:Michael Inouye\, Professor of Systems Genomics & Population Health\, Dept of Public Health & Primary Care\, University of Cambridge \n\n\n\n \n\n\n\nregistration\n\n\n\nClinical Talks \n\n\n\nClinical Talks is an educational seminar series open to everyone. It is organized by the SciLifeLab Precision Medicine Capability\, and invites a mixture of speakers that are experts with a clinical perspective on topics concerning rare diseases\, cancer\, microbiology and bioinformatics. \n\n\n\nHealth is individual and patients can benefit greatly from personalized treatments\, tailored for their specific molecular disposition. This rapidly emerging field\, known as Precision Medicine\, relies on technology development and requires close collaboration between scientists and healthcare professionals. SciLifeLab aims to bring cutting-edge technologies\, first-class expertise and data infrastructure to build the foundation of tomorrow’s Precision Medicine.
URL:https://www.scilifelab.se/event/systems-genomics-for-population-health-from-risk-prediction-to-aetiology/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2024/01/Clinical-Talks-sq.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240216T090000
DTEND;TZID=Europe/Stockholm:20240216T093000
DTSTAMP:20260527T140900
CREATED:20240129T102244Z
LAST-MODIFIED:20240213T113142Z
UID:10001128-1708074000-1708075800@www.scilifelab.se
SUMMARY:AI for Breast Cancer Risk Prediction
DESCRIPTION:I will describe the shortcomings of current breast cancer screening programs which are based on mammography for everyone. I will discuss how we developed an approach based on artificial intelligence to analyze mammograms of supposedly healthy women. The system considers three aspects\, long-term risk\, mammographic masking and subtle cancer signs. We developed the method\, analyzed the performance in retrospective data and performed a clinical study – ScreenTrustMRI. Given the same budget of additional MRI\, the AI approach detected around four times more cancers than would have been expected from established methods based on simplistic estimates of mammographic density. \n\n\n\nFredrik Strand\, Karolinska Institutet \n\n\n\n \n\n\n\nregistration\n\n\n\nClinical Talks \n\n\n\nClinical Talks is an educational seminar series open to everyone. It is organized by the SciLifeLab Precision Medicine Capability\, and invites a mixture of speakers that are experts with a clinical perspective on topics concerning rare diseases\, cancer\, microbiology and bioinformatics. \n\n\n\nHealth is individual and patients can benefit greatly from personalized treatments\, tailored for their specific molecular disposition. This rapidly emerging field\, known as Precision Medicine\, relies on technology development and requires close collaboration between scientists and healthcare professionals. SciLifeLab aims to bring cutting-edge technologies\, first-class expertise and data infrastructure to build the foundation of tomorrow’s Precision Medicine.
URL:https://www.scilifelab.se/event/ai-for-breast-cancer-risk-prediction/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2024/01/Clinical-Talks-sq.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230512T090000
DTEND;TZID=Europe/Stockholm:20230512T093000
DTSTAMP:20260527T140900
CREATED:20230201T125652Z
LAST-MODIFIED:20230228T152444Z
UID:10000800-1683882000-1683883800@www.scilifelab.se
SUMMARY:[Clinical Talks] When ends meet\, molecular tools for clinical good
DESCRIPTION:Ulf Landegren\n\n\n\nUppsala University \n\n\n\n\n\n\n\nUlf Landegren received his MD and PhD in Uppsala\, Sweden\, before spending five years at California Institute of Technology. As professor of molecular medicine in Uppsala his research focuses on developing molecular tools to meet needs in basic research and medicine\, from analyses of genetic variation with techniques such as oligonucleotide ligation assays and padlock probes to protein assays using oligonucleotide-conjugated antibodies in proximity assays for measuring protein expression levels in liquid samples or imaging their distribution in situ. Professor Landegren is a member of EMBO\, the Royal Swedish Academy of Sciences and the Royal Society of Sciences at Uppsala. He is member of several academic or industrial boards and advisory boards. He has authored 230 peer-reviewed publications\, and he is inventor of some 50 patents or applications. Work in his lab has so far given rise to 12 spin-out companies with a combined staff of more than 900 people\, including two companies that are publicly traded (Olink Proteomics and Q-linea). Technologies from his lab have also been licensed to many leading international biotech and diagnostic companies. \n\n\n\n \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Michael Akhras \n\n\n\n\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, together with Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-when-ends-meet-molecular-tools-for-clinical-good/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230421T090000
DTEND;TZID=Europe/Stockholm:20230421T093000
DTSTAMP:20260527T140900
CREATED:20230201T124434Z
LAST-MODIFIED:20230223T104655Z
UID:10000799-1682067600-1682069400@www.scilifelab.se
SUMMARY:[Clinical Talks] Molecular Pixelation: unlocking the power of single cell proteomics
DESCRIPTION:Alvaro Martinez Barrio and Filip Karlsson\n\n\n\n\n\n\n\nÁlvaro Martinez BarrioÁlvaro brings 15+ year in the computational biology field to Pixelgen. He has worked in NGS tech/analysis for over 10 years. Before Pixelgen Álvaro was a single-cell expert and group leader at 10X Genomics. Álvaro is one of the co-founders of Pixelgen Technologies. \n\n\n\n \n\n\n\n\n\n\n\nFilip KarlssonFilip has 10+ years of track record of product development in biotech start-ups using RCA with SureSelect (Halo Genomics now Agilent) and Vanadis NIPT (PerkinElmer). He is the co-inventor of Molecular Pixelation and one of the co-founders of Pixelgen Technologies. \n\n\n\nPixelgen Technologies \n\n\n\nPixelgen Technologies AB was founded in 2020 by a team of passionate\, experienced innovators and entrepreneurs with a vision to bring a new spatial understanding to biology by mapping cell surface proteins and their spatial inter-relationships. The company has developed Molecular Pixelation\, a DNA-based visualization technology for analyzing cell surface proteins\, to gain novel insights into cellular activity that will advance better medicines and diagnostics. Pixelgen is headquartered in Stockholm\, Sweden. \n\n\n\n \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Michael Akhras and Päivi Östling \n\n\n\n\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, together with Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-molecular-pixelation/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230331T090000
DTEND;TZID=Europe/Stockholm:20230331T093000
DTSTAMP:20260527T140900
CREATED:20230201T123912Z
LAST-MODIFIED:20230223T104534Z
UID:10000798-1680253200-1680255000@www.scilifelab.se
SUMMARY:[Clinical Talks] Genetic Testing for a Global Community
DESCRIPTION:Samuel Myllykangas\n\n\n\nBiography \n\n\n\nSamuel Myllykangas\, adjunct Professor at the Institute of Biomedicine\, University of Helsinki\, and co-founder of Blueprint Genetics. Samuel started his career by designing an entirely new method of sequencing the DNA (Oligonucleotide-Selective Sequencing) while working on his post-doctorate in the Stanford University. This method\, published in Nature\, sparked an idea of his own genetics company where he could apply his invention in the diagnostics of rare disease patients. Since then\, Samuel has built an extensive experience in developing genomics technologies\, bioinformatics tools and genetic testing solutions for rare diseases. Samuel runs Specialty Genetics at Quest Diagnostics and is the Managing Director of Blueprint Genetics. He is responsible for the overall success of the business\, leading the development and execution of strategy and delivering on financial and operational targets. \n\n\n\nBlueprint Genetics \n\n\n\nBlueprint Genetics is a genetic testing company focused on inherited diseases. With a patient-first mindset\, we deliver high-quality genetic testing to the global clinical community across 14 medical specialties. By combining a state-of-the-art laboratory process\, the latest sequencing technology\, AI empowered data-crunching tools and techniques\, world-class professionals\, and a holistic customer experience approach\, we are bringing genetic knowledge to mainstream healthcare. Blueprint supports clinicians and their patients with comprehensive and high-quality tools and resources for diagnosis of genetic conditions. In doing so\, we provide possibilities for targeted treatment and individualized care for patients. \n\n\n\n\n\n\n\n \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Päivi Östling\, SciLifeLab \n\n\n\n\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, together with Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-genetic-testing-for-a-global-community/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230310T090000
DTEND;TZID=Europe/Stockholm:20230310T093000
DTSTAMP:20260527T140900
CREATED:20230130T170847Z
LAST-MODIFIED:20230223T120445Z
UID:10000795-1678438800-1678440600@www.scilifelab.se
SUMMARY:[Clinical Talks] The PONCH study
DESCRIPTION:The PONCH Study of the influence of diet\, obesity and gestational diabetes (GDM) on maternal and child metabolic health\n\n\n\nUlrika Andersson Hall\n\n\n\nUniversity of Gothenburg \n\n\n\n\n\n\n\nUlrika is currently an associate professor and project manager of the Pregnancy Obesity Nutrition and Child Health (PONCH) study headed by professor Agneta Holmäng at the Institute of Neuroscience and Physiology\, Sahlgrenska Academy\, University of Gothenburg. Ulrika has an MSc in Molecular Biotechnology from Uppsala University and a PhD in Biochemistry from Oxford University. In 2015\, after post-doctoral positions at the Medical Research Center of Imperial College\, London\, and at the Department of Food and Nutrition and Sport Science\, University of Gothenburg\, she joined the PONCH group. She now runs the PONCH study focusing on maternal and child metabolic health during and after pregnancy\, but has also added other branches to the study\, particularly with focus on the transition from gestational diabetes to type-2-diabetes. \n\n\n\nThe PONCH study: \n\n\n\nPONCH started in 2009 and is an ongoing prospective\, longitudinal study investigating the influence of diet\, obesity and gestational diabetes (GDM) on maternal and child metabolic health. The specific aims of PONCH are to better understand how body composition\, insulin resistance and energy metabolism change during and after pregnancy in women of normal body weight\, with obesity or with GDM\, and how this affects the body composition and health of their children. Another important aim is to evaluate insulin resistance after GDM in order to better be able to predict the development of type-2-diabetes in these women. Here\, we also investigate the effect of life-style factors in the transition from GDM to type-2-diabetes. Our hope is that the research will influence future clinical care of women with GDM. \n\n\n\n \n\n\n\n \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Päivi Östling\, SciLifeLab \n\n\n\n\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, and brought to you by Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-the-ponch-study/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230210T090000
DTEND;TZID=Europe/Stockholm:20230210T093000
DTSTAMP:20260527T140900
CREATED:20230130T122543Z
LAST-MODIFIED:20230130T122829Z
UID:10000794-1676019600-1676021400@www.scilifelab.se
SUMMARY:[Clinical Talks] A co-creation engine for the next Generation Life Science ventures
DESCRIPTION:Bobby Kaura\n\n\n\nSeed Investment\, Global Entrepreneurial & Ecosystem Development @ Illumina For Startups \n\n\n\nIllumina Inc.At Illumina\, we’re committed to unlocking the power of the genome\, and we know we can’t do it alone. Illumina for Startups is our way of accelerating innovation in the entrepreneurial community by partnering with leading venture capital investors and entrepreneurs to create\, launch and grow genomics startups. Together\, we’re advancing breakthrough applications in genomics\, including therapeutics\, diagnostics\, agriculture\, synthetic biology\, software and direct-to-consumer applications. \n\n\n\nIllumina Accelerator is a company creation engine co-located with Illumina research and development sites in San Francisco Bay Area and Cambridge\, UK. Since inception\, Illumina Accelerator has invested in 70+ genomics startups from across the globe\, which have collectively raised over $1 billion in venture capital funding. Approximately 93% of Illumina Accelerator investments have gone on to raise additional capital from leading investors. \n\n\n\nOther global models to catalyse genomics startups include the following initiatives: Sequoia Capital China Intelligent Healthcare Genomics Incubator powered by Illumina\, Illumina for Start-ups Australia\, Illumina for Start-ups Singapore\, Illumina for Start-ups Grants\, and Illumina for Start-ups Networks. \n\n\n\nMultiplAI HealthMultiplAI is a biotech startup developing universal genomic screening for cardiovascular diseases using RNA sequencing and machine learning. They are bringing liquid biopsy to cardiovascular disease. They have a proprietary laboratory-validated prototype and are conducting pilot clinical studies aiming to achieve initial clinical validation of their whole-blood liquid biopsy approach in the cardiovascular space. MultiplAI is based in London\, UK\, with clinical and lab operations in Cambridge\, UK\, and Buenos Aires\, Argentina. MultiplAI Health has attended the Illumina Accelerator program. \n\n\n\n\n\n\n\nBobby Kaura\, MScBobby has supported the creation of Illumina For Startups\, a platform and portal for entrepreneurial and ecosystem development initiatives\, with startups\, entrepreneurs\, investors and lifesciences stakeholders. He co-launched Illumina Accelerator Cambridge UK\, the flagship initiative under Illumina For Startups\, and the second location for Global Illumina Accelerator which is a genomics and VC backable company creation engine. In his current role\, he looks to grow the life sciences and genomics ecosystem\, supporting UK Plc.\, and globally\, by partnering with entrepreneurs\, investors and individuals within the innovation/entrepreneurial community\, to support entrepreneurs with access to funding\, sequencing\, coaching and facilities and to create new models of innovation. Previously\, he was responsible for heading commercial market and business development for Illumina EMEA. His focus was on how the application of genomics enables precision health. \n\n\n\nBefore joining Illumina\, he worked in the NHS to deliver sustainable transformation programs\, early founder team for US based startup and spent several years working in the pharma industry. \n\n\n\nHe is a member of the advisory board at Praesens Foundation (non-profit)\, Expert in Residence at Cambridge Judge Business School & Oxford University Translational Research Office and member of NHS Innovation Accelerator panel. In addition\, he advises health\, tech and blockchain startups. \n\n\n\nBobby read his B.Sc in Biology\, with a focus on neuroscience and genomics\, and an M.Sc in IT from the Queen Mary University of London. \n\n\n\n\n\n\n\nDr. Santiago Miriuka\, MD MSc PhDSantiago is the co-founder and CEO/CTO of MultiplAI Health. He is a Medical Doctor with 20+ years in clinical cardiology. Director of a basic and translational lab working on cutting-edge cellular and molecular biology. Data scientist and coder looking to innovate in medicine. \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Michael Akhras\, Colibri Ventures \n\n\n\n\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, and brought to you by Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-a-co-creation-engine-for-the-next-generation-life-science-ventures/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221216T090000
DTEND;TZID=Europe/Stockholm:20221216T093000
DTSTAMP:20260527T140900
CREATED:20220923T091314Z
LAST-MODIFIED:20221201T124338Z
UID:10000688-1671181200-1671183000@www.scilifelab.se
SUMMARY:[Clinical Talks] Functional precision medicine using AI drug discovery
DESCRIPTION:Greg Vladimer\n\n\n\nVice President\, Translational Research at Exscientia \n\n\n\n\n\n\n\nGreg Vladimer\, VP\, Translational Research joined Exscientia through the acquisition of Allcyte\, a pioneer in the field of AI-first functional precision oncology and translational cancer research\, where he was a Scientific Co-Founder and the Chief Scientific Officer. At Allcyte\, he and his team pushed the boundaries of translational cancer research through the use of disease relevant primary human cancer samples\, high content imaging\, custom AI-powered computer vision\, and scalable cloud computing. Greg has a PhD from University of Massachusetts Medical School in Immunology\, after which he moved to Vienna as an EMBO-supported Postdoctoral Fellow at CeMM where he and a colleague invented the first-generation platform used for the translational work\, and spearheaded the first ever prospective interventional clinical trial showing that drugs prioritised using a functional precision medicine tool had clinical benefit for late stage blood cancer patients. \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Päivi Östling\, SciLifeLab \n\n\n\n\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, and brought to you by Colibri Ventures.
URL:https://www.scilifelab.se/event/functional-precision-medicine-using-ai-drug-discovery/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221201T173000
DTEND;TZID=Europe/Stockholm:20221201T180000
DTSTAMP:20260527T140900
CREATED:20220831T154601Z
LAST-MODIFIED:20221110T115015Z
UID:10000665-1669915800-1669917600@www.scilifelab.se
SUMMARY:[Clinical Talks] Recording biology to the genome itself
DESCRIPTION:Jay Shendure\n\n\n\nProfessor of Genome Sciences at the University of Washington \n\n\n\n\n\n\n\nJay Shendure is a Investigator of the Howard Hughes Medical Institute\, Professor of Genome Sciences at the University of Washington\, Director of the Allen Discovery Center for Cell Lineage Tracing\, and Scientific Director of the Brotman Baty Institute for Precision Medicine. \n\n\n\nHis 2005 doctoral thesis with George Church included one of the first successful reductions to practice of next generation DNA sequencing. Dr. Shendure’s research group in Seattle pioneered exome sequencing and its earliest applications to gene discovery for Mendelian disorders and autism; cell-free DNA diagnostics for cancer and reproductive medicine; massively parallel reporter assays\, saturation genome editing; whole organism lineage tracing\, and massively parallel molecular profiling of single cells.Dr. Shendure is the recipient of the Curt Stern Award from the American Society of Human Genetics (2012)\, the Richard Lounsbery Award from the National Academy of Sciences (2019) and the Mendel Award from the European Society of Human Genetics (2022) and is an elected member of the American Association for the Advancement of Science (AAAS) and the National Academy of Sciences (NAS). He serves or has previously served as an advisor to the NIH Director\, the US Precision Medicine Initiative\, the National Human Genome Research Institute\, the Chan-Zuckerberg Initiative and the Allen Institutes for Cell Science and Immunology. He received his MD and PhD degrees from Harvard Medical School in 2007. \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Michael Akhras\, Colibri Ventures \n\n\n\n\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, and brought to you by Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-recording-biology-to-the-genome-itself/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221111T090000
DTEND;TZID=Europe/Stockholm:20221111T093000
DTSTAMP:20260527T140900
CREATED:20220923T085744Z
LAST-MODIFIED:20220928T154812Z
UID:10000687-1668157200-1668159000@www.scilifelab.se
SUMMARY:[Clinical Talks] Combining AI and in situ sequencing to explore the tumor micro-environment
DESCRIPTION:Carolina Wählby\n\n\n\nProfessor in quantitative microscopy\, SciLifeLab and Dept. IT\, Uppsala University \n\n\n\n\n\n\n\nCarolina Wählby is professor in Quantitative Microscopy at the Dept. of Information Technology\, Uppsala University\, and Scientific Director of the National SciLifeLab Bioimage Informatics Unit. Her research is focused on developing computational approaches for extracting information from image data with focus on precision medicine and life science. Methods include traditional image analysis as well as AI and deep learning for understanding dynamics of cancer tissue\, antibiotics susceptibility and spatial transcriptomics\, funded primarily by the ERC TissUUmaps project and the Swedish Foundation for Strategic research. She received the SBI2 President’s innovation award in 2014 for her work on in situ sequencing\, and the Thuréus prize in 2015 for development of open tools for image analysis. She is a member of the Royal Society of Sciences at Uppsala and the Royal Swedish Academy of Engineering Sciences. She has a MSc in molecular biotechnology and a PhD in digital image analysis\, and carried out postdoc research within genetics and pathology. She was part of the Imaging Platform of the Broad Institute of Harvard and MIT in 2009-2015 and became full professor at Uppsala University in 2014. She is a member of the steering group of a 300M€ effort on Data Driven Life Science\, funded by the Knut and Alice Wallenberg Foundation\, with the ambitious goal of training the next generation of life scientists. Her heart lies in the intersection between life science and computational image analysis\, and she is intrigued by the possibilities of technological developments and convergence of the scientific fields. \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Päivi Östling\, SciLifeLab \n\n\n\n\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, and brought to you by Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-combining-ai-and-in-situ-sequencing-to-explore-the-tumor-micro-environment/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221021T090000
DTEND;TZID=Europe/Stockholm:20221021T093000
DTSTAMP:20260527T140900
CREATED:20220831T154039Z
LAST-MODIFIED:20220928T142401Z
UID:10000664-1666342800-1666344600@www.scilifelab.se
SUMMARY:[Clinical Talks] Stanford Ignite: Lessons learned from teaching entrepreneurs
DESCRIPTION:Yossi Feinberg\n\n\n\nThe Adams Distinguished Professor of Management and Professor of Economics at Stanford Graduate School of Business (GSB) \n\n\n\n\n\n\n\nYossi Feinberg received his PhD in Mathematics from the Hebrew University in Jerusalem in 1997. His thesis studied how differing prior beliefs of decision makers can be expressed by their disagreement on current (posterior) events. After completing his dissertation under the supervision of Nobel Laureate Professor Robert J. Aumann\, Yossi began teaching economics at Kellogg Graduate School of Management. Yossi joined Stanford GSB in 1998. \n\n\n\nYossi’s teaching interests include Economics of Organization\, Managerial Economics\, Strategy\, Information Markets\, Game Theory and Applied Decision Making. In 2003 he received the MBA distinguished teaching award. \n\n\n\nYossi’s recent research interests include\, for example\, the analysis and implication of strategic decision making in the face of unawareness. He has modeled games with unawareness and their solutions. In these games each decision maker can reason about the extent to which others may only have a limited perception of the full scale of the economic interaction at hand. Yossi was an Associate Editor of the Journal of Economic Theory and is serving as a referee for all major microeconomics journals. He has given numerous invited seminars as well as multiple plenary talks at academic conferences. \n\n\n\nHe has been consulting in a wide range of industries including hi-tech\, media and healthcare as well as giving invited talks on topics such as pricing\, the sub-prime crisis\, in-house vs. outsourcing\, allocating decision power in organizations and strategic interactions. \n\n\n\nHe is the faculty director of Stanford Ignite\, a global innovation program running on the Stanford Campus. \n\n\n\nregister to receive zoom link\n\n\n\nStanford Ignite\n\n\n\nStanford Ignite grew out of a new kind of entrepreneurial educational program initiated in 2006 and spearheaded by Professor Yossi Feinberg. In aggregate\, about 1\,600 past participants have started more than 100 successful companies since the program was introduced. \n\n\n\nStanford Ignite is a certificate program that provides the business fundamentals necessary to succeed at any entrepreneurial or intrapreneurial venture. Business concepts learned in the classroom span core business skills and functional skills\, and are reinforced through practical application with team venture projects\, where participants work by project-based learning approach\, in teams of five or six to develop a new product or service for an existing organization or a new venture.Previous participants include graduate students currently pursuing a master’s\, MD\, PhD\, or post-doc program in a nonbusiness field\, with a strong representation from the Life Sciences area. A key attribute to of the success of the program is the close academic experience it offers. Participants engage directly with the same renowned faculty that teach in the Stanford MBA Program. Participation in real-time lectures\, case evaluations\, Q&A sessions\, small group discussions\, workshops\, panels\, and team projects. The program also features guest speakers from leading companies\, many of whom become venture-project mentors. \n\n\n\nKey Benefits\n\n\n\nStanford Ignite –is a certificate program that provides the business fundamentals to succeed at any entrepreneurial ventures. \n\n\n\nLearn fundamental business concepts from core business frameworks to tactical skills.Reinforce and apply lessons learned by working on a team to develop a new product or service.Improve communication\, elevator pitch\, and presentation skills in a daylong communications bootcamp.Present your idea and get robust feedback from venture capitalists\, angel investors\, industry experts\, and experienced entrepreneurs.\n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, and brought to you by Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-yossi-feinberg/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221007T090000
DTEND;TZID=Europe/Stockholm:20221007T093000
DTSTAMP:20260527T140900
CREATED:20220831T144618Z
LAST-MODIFIED:20220928T142055Z
UID:10000663-1665133200-1665135000@www.scilifelab.se
SUMMARY:[Clinical Talks] Implementing Precision Medicine from a global perspective
DESCRIPTION:Joanne M. Hackett\n\n\n\nHead of Genomic and Precision Medicine at IQVIA \n\n\n\n\n\n\n\nDr Hackett is a clinical academic\, entrepreneur\, investor\, and a strategic\, creative visionair with global experience spanning successful start-ups to Fortune 500 companies. Aside from her curious passion for life and positivity\, Joanne is known for building innovation\, driving personalised medicine and leading through fast paced\, complex changing ecosystems and integrations. Joanne’s goal is to contribute to bringing the world novel\, cost effective and simple health care solutions\, and she is particularly keen on building the case for prevention\, open science and citizen genomics. She has extensive global experience across academic\, business and clinical institutions\, and enjoys sharing her experiences with the Boards she sits on as well as companies she provides strategic advice to. \n\n\n\nJoanne has been publicly recognised for her relentless pursuit of revolutionising healthcare and has been named one of the top six Influential Leaders in Healthcare by CIO Look\, the Accenture Life Science Leader of the year\, Freshfields Top 100 Most Influential Women\, One HealthTech Top 70 Women in the NHS\, Pharmaceutical Market Europe’s 30 women leaders in UK healthcare and BioBeat Top 50 Women in Biotech Award. Joanne believes in human courage and perseverance against the odds\, and demonstrates that positive change\, whether in a company or in one’s personal life\, can be carved out from even the greatest of trials. As a believer of ‘health = wealth’\, Joanne is an internationally known yoga instructor. \n\n\n\nregister to receive zoom link\n\n\n\nModerator: Richard Rosenquist Brandell\, Genomic Medicine Sweden \n\n\n\nIQVIA Inc.\n\n\n\nIQVIA is a leading global provider of advanced analytics\, technology solutions\, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics\, transformative technology\, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82\,000 employees\, IQVIA conducts operations in more than 100 countries. \n\n\n\nIQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech\, medical device and pharmaceutical companies\, medical researchers\, government agencies\, payers and other healthcare stakeholders tap into a deeper understanding of diseases\, human behavior and scientific advances\, in an effort to advance their path toward cures. To learn more\, visit www.iqvia.com. \n\n\n\n \n\n\n\nClinical Talks\n\n\n\nClinical Talks is back for more! With a brand new and shiny Season 6. After successfully completing 5 seasons with > 70 enthusiastic Clinical Talkers to our record\, we have barely scratched the surface of all the amazing work our clinical\, academic and industry Life Science community has to offer. More about the upcoming events is available here. \n\n\n\nThese events are co-organized by Karolinska Institutet Innovations AB and SciLifeLab\, and brought to you by Colibri Ventures.
URL:https://www.scilifelab.se/event/clinical-talks-implementing-precision-medicine-from-a-global-perspective/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2022/08/Square-500x500-Clinical-Talks@4x.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220506T090000
DTEND;TZID=Europe/Stockholm:20220506T093000
DTSTAMP:20260527T140900
CREATED:20220217T115711Z
LAST-MODIFIED:20220331T141218Z
UID:10000531-1651827600-1651829400@www.scilifelab.se
SUMMARY:[Clinical Talks] iCAN and developing a national precision cancer medicine program
DESCRIPTION:On May 6\, Professor Tomi Mäkelä at the University of Helsinki Faculty of Medicine will talk about his work as executive officer of the iCAN Digital Precision Cancer Medicine flagship. iCAN is one of the Academy of Finland national research and innovation flagships for 2019-2026\, with the goal to develop a nucleus of scientific excellence into competence clusters for discoveries\, innovations\, and societal and economic impact. The founding hosts are the University of Helsinki and HUS Helsinki University Hospital with a goal for national reach within the National Cancer Center FICAN. While executed as a public-private-patient-partnership\, iCAN brings together academic research\, healthcare system\, life science industry partners and patients. The active participation of patients at all levels is a key element of the flagship\, ensuring impact and benefits to the patients. Partnerships with companies from pharma\, biotech\, and AI sectors are critical and enable the inclusion of early drug leads\, new technologies\, and new competencies. Furthermore\, iCAN leverages the unique strengths that Finland has in the areas of top-level cancer research\, health registries\, biobanks\, and digital health to provide solutions for the global cancer challenge. \n\n\n\nRegistration\n\n\n\nTomi Mäkelä\, MD\, PhD\, is a Professor of Biochemistry and Molecular Biology at the University of Helsinki Faculty of Medicine\, and the Executive Officer of the Finish iCAN Digital Precision Cancer Medicine flagship program. He obtained an MD and PhD in Oncology and Cancer Biology during his studies in the late 80\, early 90s at the University of Helsinki. He then pursued his postdoctoral studies at the prestigious Whitehead Institute\, Cambridge Massachusetts 1993-1995\, and in 2002 became a Professor at the University of Helsinki. Since\, then he has held various leadership positions at the University\, including\, Director of the Institute of Biotechnology (2009-2014)\, Director of HiLIFE Helsiniki Institute of Life Science (2015-2019)\, Director of Biomedicum Helsinki (2017-present). Prof. Mäkelä is also the current Executive Manager of The Finnish Cancer Institute (since 2012)\, and a panelist and panel chair of the European Research Council since 2011. \n\n\n\nThe iCAN Digital Precision Cancer Medicine flagship is one of six national flagships in Finland 2019-2026 aiming to develop nuclei of scientific excellence into competence clusters for discoveries\, innovations\, and societal and economic impact. In iCAN a platform joining Precision Cancer Medicine (PCM) with Digital Health is established for discoveries and improved treatments. iCAN is hosted by the University of Helsinki and Helsinki University Hospital HUS and with a goal for national reach within the National Cancer Center FICAN. Leveraging the unique strengths that Finland has in the areas of top-level cancer research\, health registries\, biobanks\, and digital health to provide solutions for the global cancer challenge. iCAN is furthermore organized as a partnership between academic research\, healthcare system\, life science industry partners and patients. It is a public-private-patient-partnership\, forming a competence cluster with significant economic\, educational\, and societal impact. The active participation of patients at all levels is a key element of the flagship\, ensuring impact and benefits to the patients. Partnerships with companies from pharma\, biotech\, and AI sectors are critical and enable the inclusion of early drug leads\, new technologies\, and new competencies. \n\n\n\nThese ambitious goals are accomplished via the unique iCAN digital precision cancer medicine platform\, enabling the integration of cutting-edge molecular profiling information from tumors with rich longitudinal health data available in Finland\, by eg. addressing tumor development in the context of the immune system or development of treatment resistance. The iCAN discovery platform links molecular profiling of tumors with broader health data of cancer patients\, acting as a catalyst for breakthrough research and technologies.The scale of data – 15\,000 samples across different cancer types will be profiled by 2026 – enables real impact and broad studies across different cancer types. The platform will enable an improved understanding of the complex interplay between cancer cells and the host.The pan-cancer research project already has ongoing studies in colorectal\, gastric\, pancreatic\, breast\, lung\, ovarian\, renal\, prostate\, bladder\, melanoma\, and pediatric solid cancers as well as myeloid leukemias\, lymphomas and multiple myeloma. \n\n\n\nRead more\n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/clinical-talks-ican-and-developing-a-national-precision-cancer-medicine-program/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220422T090000
DTEND;TZID=Europe/Stockholm:20220422T093000
DTSTAMP:20260527T140900
CREATED:20220330T133354Z
LAST-MODIFIED:20220405T153635Z
UID:10000575-1650618000-1650619800@www.scilifelab.se
SUMMARY:[Clinical Talks] Introduction to AI-driven image analysis in pathology: from preclinical research to clinical diagnostics
DESCRIPTION:Dr. Sami Blom leads Aiforia’s application development team with an ambition to build impactful image analysis solutions to advance histopathology. He has a background in the fields of translational cancer research and pathology and he has extensive expertise in staining and imaging methods for histology specimens. Dr. Blom joined Aiforia in 2016 to develop and advance Aiforia’s applications\, products and services. \n\n\n\nIntroduction to AI-driven image analysis in pathology: from preclinical research to clinical diagnostics \n\n\n\nAiforia equips pathologists and scientists with powerful deep learning artificial intelligence for translating images into discoveries\, decisions\, and diagnoses. The cloud based Aiforia software aims to escalate the efficiency and precision of preclinical and clinical medical image analysis from oncology to neuroscience and more. Deep learning artificial intelligence enables increased speed\, accuracy and consistency in medical image analysis.  \n\n\n\nAiforia was founded in 2013 and our mission is to provide the highest quality solutions for AI-assisted image analysis to enable personalized and democratized care for patients. Year 2021 was historic for the company: Aiforia was listed on Nasdaq Helsinki First North Market Finland in December 2021. In connection with the listing\, the Company raised approximately 29 million euros in gross assets. This\, together with the B-financing round implemented earlier in the same year\, provides a strong foundation for Aiforia’s growth. \n\n\n\nRegister to receive zoom link\n\n\n\n \n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/clinical-talks-introduction-to-ai-driven-image-analysis-in-pathology/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220408T090000
DTEND;TZID=Europe/Stockholm:20220408T093000
DTSTAMP:20260527T140900
CREATED:20220330T131410Z
LAST-MODIFIED:20220330T132843Z
UID:10000574-1649408400-1649410200@www.scilifelab.se
SUMMARY:[Clinical Talks]Seeing is believing\, unraveling the discovery of a centimeter-long macro-bacteria
DESCRIPTION:On April 8\, Dr. Jean-Marie Volland\, Scientist at Berkeley Lab and Laboratory for Research in Complex Systems (LRC Systems)\, and Shailesh Date\, CEO of LRC Systems (Adj. Assoc. Professor at UCSF)\,will talk about their recent discovery and characterization of the macro-bacteria Ca. Thiomargarita magnifica. The threadlike single-cell bacterium\, commonly found in the Caribbean Mangroves\, is visible to the naked eye\, and able to grow up to 2 centimeters in length. In a recent effort\, an international team studied the “magnificent” organism using fluorescence\, x-ray\, and electron microscopy\, and fully sequenced the genome.  \n\n\n\nThrough a unique strategy of polyploidy\, along with compartmentalization of genomic material and protein synthesis in membrane-bound organelle\, the organism has been able to grow orders of magnitude over the theoretical limits for bacterial cells. The traditional view\, which has almost become dogmatic\, is that prokaryotes (bacteria and single-cell microbes) have free-floating DNA\, whereas eukaryotes (yeast and multicellular organisms) package their DNA in a nucleus. This new model organism blurs that line and offers amazing potential insights into biological evolutionary strategies\, many of which are as yet unexplored. One can only wonder at the type and number of new clinical innovations that will emerge as we continue exploring the frontiers of biology and biological complexity. \n\n\n\nRegister to receive zoom link\n\n\n\n  \n\n\n\n\n\n\n\nJean-Marie Volland is a Scientist at Lawrence Berkeley National Laboratory (Berkeley Lab) and at Laboratory of Research in Complex Systems (LRC Systems) in Menlo Park California. He obtained his PhD at the Université des Antilles\, in the French West Indies\, studying biology and tropical ecology in the Indian Ocean and Caribbean. Jean-Marie then continued to pursue his Postdoctoral research at University of Vienna\, Austria during 2012-2017. Initially in the Monika Bright´s Lab at the Department of Limnology and Biological Oceanography studying symbiosis in chemosynthetic ecosystems\, and then also in the Silvia Bulgheresi´s Lab at the Archea Biology and Ecogenomics Division studying tropical ecology pathways of microorganisms. In 2018 Jean-Marie joined the Berkeley Lab as an affiliate Scientist to continue working on uncovering highly divergent forms of life together with LRC Systems. The story of the discovery of Thiomargarita magnifica dates back a decade ago\, when marine biologist Olivier Gros\, from the Université of Antilles\, first discovered microbial filaments on leaves buried in the mangrove of Guadeloupe. Gros lab member and microbiologist colleague Silvina González-Rizzo identified it to be in fact be one bacterium. Jean-Marie\, together with his Université of Antilles colleagues and LRC Systems set forth to methodologically study and categorize the new organism. \n\n\n\n\n\n\n\nShailesh Date is the CEO and Founder of Laboratory for Research in Complex Systems (LRC Systems). He is also Adjunct Professor of Biology at San Francisco State University and an Associate Adjunct Professor of Epidemiology and Biostatistics at the University of California San Francisco (UCSF). Shailesh obtained his PhD at The University of Texas\, Austin in Molecular Biology in 2004\, and completed a postdoctoral fellowship at the University of Pennsylvania School of Medicine in 2008\, focusing on computational biology of infectious diseases. Between 2008-2015\, Shailesh worked as a scientist at Genentech\, and during a brief sabbatical in 2013\, completed the prestigious Ignite Program at the Stanford Graduate School of Business. He left Genentech in 2015 to join Global Viral (GV)\, a nonprofit organization with roots in public health research. He founded the LRC Systems in 2019\, transforming Global Viral into a new organization focused on complex systems research in a wide variety of areas. \n\n\n\nAbout Global Viral and LRC SystemsGlobal Viral was founded by Nathan Wolfe in 2007 as the Global Viral Forecasting Initiative (GVFI)\, focusing on public health and field epidemiology while supporting programs like HIV prevention run by USAID\, WHO and other similar organizations in Africa and South East Asia.In 2012\, the organization split into Metabiota\, a for-profit company that took over epidemiology and forecasting-related work\, and Global Viral\, a nonprofit that retained and concentrated on basic research.In 2019\, under the leadership of a new Chief Executive and a new board\, the organization reoriented its research towards complex systems and adopted the “Laboratory for Research in Complex Systems (LRC Systems)”\, which was initially founded as a new division within GV\, as its new name.https://www.lrc.systems \n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/seeing-is-believing-unraveling-the-discovery-of-ca-thiomargarita-magnifica-a-centimeter-long-macro-bacteria/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220318T090000
DTEND;TZID=Europe/Stockholm:20220318T093000
DTSTAMP:20260527T140900
CREATED:20220117T165753Z
LAST-MODIFIED:20220308T081854Z
UID:10000510-1647594000-1647595800@www.scilifelab.se
SUMMARY:True precision medicine in immuno-oncology\, challenges\, and opportunities
DESCRIPTION:Sara Mangsbo\, biträdande universitetslektor vid institutionen för farmaceutisk biovetenskap\, Immunonkologi.\n\n\n\n\n\nOn March 18\, Uppsala University Associate Professor Sara Mangsbo will talk about how the future of cancer therapy is becoming personal. Sara co-founded Strike Pharma to further develop the Uppsala University and SciLifeLab Drug Discovery platform co-developed ADAC technology (Adaptable Drug Affinity Conjugates).  \n\n\n\nWith current diagnostic tools also\, immunotherapy can and should enter the omics-field and the developed delivery platform envisions a truly patient tailored neoantigen cancer vaccine strategy\, ensuring that the body becomes the factory to generate tumor-specific T cells\, that can find and destroy tumor cells regardless of the location in the body. With a cost and time efficient “True Precision Medicine” approach\, tailored therapeutics will be a realistic future\, ultimately lowering the healthcare burden for a sustainable future. \n\n\n\nSara Mangsbo \n\n\n\nregister to receive zoom link\n\n\n\nSara Mangsbo is a Senior Lecturer in Antibody Drugs at Uppsala University at the Department of Pharmacy. She has her education background with a PhD in Clinical Immunology Uppsala University. Sara has since completed her postdoctoral studies at Leiden University Medical Center and started her own research group at Uppsala University in 2016. Her work focuses on the development and immunological characterization of novel immunotherapies and therapeutic combination strategies for drug discovery. Sara has previously also held a brand lead position in Immuno-oncology at Astra Zeneca’s marketing division and co-founded the drug development and service company startups Immuneed AB and VivoLogica AB (current board member). The drug development platform from Immuneed was acquired by the Norwegian pharmaceutical company Ultimovacs in 2018.  \n\n\n\nIn late 2020\, Sara co-founded Strike Pharma AB. Strike Pharma develops a novel next generation Antibody-Drug Conjugate (ADC) technology\, the ADAC technology. ADACs are short for Adaptable Drug Affinity Conjugates and are built to improve deliver tailored made synthetic peptides to specific cell types for improved immune modulation. Using the ADAC platform\, efficient delivery and extended half-life of patient tailored peptide therapeutics will ensure that the body becomes the factory\, producing billions of T cells that can find and destroy tumors cells regardless of the location in the body. \n\n\n\n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/true-precision-medicine/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220218T090000
DTEND;TZID=Europe/Stockholm:20220218T093000
DTSTAMP:20260527T140900
CREATED:20220117T165253Z
LAST-MODIFIED:20220117T171034Z
UID:10000509-1645174800-1645176600@www.scilifelab.se
SUMMARY:Spearheading the cardiovascular precision medicine with innovative medical tools
DESCRIPTION:On February 18\, we have invited Dr. Tero-Pekka Alastalo\, to give a talk about his experience with co-founding the precision medicine company Blueprint Genetics in 2012. What started out as a technology development spinout from Stanford University\, quickly grew to a global genetic testing company with >200 employees (acquired by Quest Diagnostics in 2020). With a solid background in pediatric cardiology and cardiovascular research\, Tero-Pekka recently joined CardioSignal by Precordior as the Chief Medicinal Officer and General Manager of the US operations. During his talk\, he will share his insights on how technology can revolutionize the medical methodology for a sustainable future and better use of resources. \n\n\n\nRegister to receive zoom link\n\n\n\n\n\n\n\nTero-Pekka Alastalo\, MD\, PhD\, is the Chief Medical Officer and General Manager of the US operations at CardioSignal by Precordior. He also co-founded Blueprint Genetics in 2012. Tero-Pekka obtained his MD\, PhD degree at the University of Turku in 2001. After 6 years of fellowships in pediatrics at the University of Turku\, he pursued his postdoctoral studies at Stanford University in basic research on cardiovascular biology and disease in the Marlene Rabinovitch Lab during 2007-2009. Upon returning to Finland\, he joined the University of Helsinki as a PI studying molecular and genetic mechanisms of cardiovascular diseases\, as well as a pediatric cardiology fellowship. In 2012 he joined forces with fellow Stanford postdoc Samuel Myllykangas to co-found Blueprint Genetics and held various management roles including Chief Medical Officer until September 2021\, when he joined CardioSignal. \n\n\n\nBlueprint Genetics is a genetic testing company focused on inherited diseases. With a patient-first mindset\, the company delivers high-quality genetic testing to the global clinical community (<4000 clinicians) across 15 medical specialties. Blueprint Genetics is based in Helsinki and Seattle\, with a customer base spanning over 70 countries. By combining a state-of-the-art laboratory process\, the latest sequencing technology\, AI empowered data-crunching tools and techniques\, world-class professionals\, and a holistic customer experience approach\, genetic knowledge is introduced to mainstream healthcare. Blueprint Genetics was acquired by Quest Diagnostics in 2020. \n\n\n\nCardioSignal by Precordior is a scientific forerunner in the field of cardiac motion sensing\, especially chest micro-rotation via micro-electromechanical sensors (MEMS) with some 30 scientific articles published in the area\, including in the prestigious journals Circulation and Nature Scientific Reports. The academic research studying the heart via chest micro-motions started at the University of Turku in January 2012. Continuing this work\, scientists at Precordior work today in close collaboration with researchers and cardiologists at several universities and hospitals. CardioSignal offers an easy and reliable detection of heart disease to people worldwide at an affordable price\, with an application that is accurate and reliable enough to serve physicians\, while easy and accessible enough to empower consumers. This is achieved via a smartphone application that transforms a phone into a device that can detect atrial fibrillation and\, in the future\, other heart conditions as well. \n\n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/spearheading-the-cardiovascular-precision-medicine-with-innovative-medical-tools/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220204T090000
DTEND;TZID=Europe/Stockholm:20220204T093000
DTSTAMP:20260527T140900
CREATED:20220117T164155Z
LAST-MODIFIED:20220117T171054Z
UID:10000508-1643965200-1643967000@www.scilifelab.se
SUMMARY:IMPRESS-Norway and implementing precision cancer medicine in Norway
DESCRIPTION:On February 4\, oncologist\, and Head of Research at Division of Cancer Medicine at Oslo University Hospital Professor Åslaug Helland will give a talk about her mission with the clinical precision medicine study IMPRESS-Norway that she co-founded in 2021. She is also a Professor at the University of Oslo. Åslaug is the PI of the IMPRESS-N study with the goal of “Improving public cancer care by implementing precision medicine in Norway\,” and it is a national clinical study for patients with advanced cancer after standard therapy\, with multiple Norwegian healthcare partners as well as industry collaborators. The effort is preparing Norway towards the many sustainable future benefits precision medicine has to offer for future healthcare solutions (Read more). \n\n\n\nregister to receive zoom link\n\n\n\nBiography \n\n\n\n\n\n\n\nÅslaug Helland\, MD\, PhD\, is a Group leader at the Institute for Cancer Research\, Norwegian Radium Hospital (NRH)\, Oslo\, Norway\, and Senior oncologist\, Dept of Oncology\, Oslo University Hospital\, Radiumhospital. She is also Professor at the University of Oslo Institute of Clinical Medicine. Åslaug obtained her MD degree in 1995\, and later her PhD in Medicine in 2000\, from the University of Oslo. She pursued her postdoctoral studies during 2003/2004 at Stanford University\, and in 2007/2008 as a visiting scientist at the Peter MacCallum Cancer Centre in Melbourne Australia\, adding to her international experience. Åslaugs research group focuses on translational studies on solid tumours\, with a special interest in pancreatic cancers\, lung cancers\, ovary cancers and colorectal cancers. They perform whole genome analyses on patient material\, aiming at identifying predictive and prognostic biomarkers as well as more targeted analyses for the identification of pathways and immune mechanisms of interest. By increasing the understanding of the underlying biology of tumour development\, they aim at improving cancer patient care. She furthermore led several clinical and translational studies in lung cancer. \n\n\n\nÅslaug is the PI of the IMPRESS-Norway study with the goal of “Improving public cancer care by implementing precision medicine in Norway\,” and it is a national clinical study for patients with advanced cancer after standard therapy. During 2019\, Oslo Cancer Cluster hosted a series of workshops with public and private stakeholders in cancer with the goal to accelerate the implementation of cancer precision medicine in Norway. The initial idea for IMPRESS emerged in one of these workshops. A dedicated team at Oslo University Hospital quickly turned it into a national effort together with colleagues at university hospitals across Norway. \n\n\n\nIMPRESS involves the active support of leading global pharmaceutical companies that will provide the study drugs and contribute with per patient fees. Public funding will help to ensure this innovative study paves the way for more cancer clinical trials in Norway. National infrastructure for precision diagnostics is needed and is currently being set up at all Norwegian cancer hospitals. Cancer patients who are eligible for clinical trials can soon be tested and selected based on their specific genetic profile. \n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/impress-norway-and-implementing-precision-cancer-medicine-in-norway/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211126T090000
DTEND;TZID=Europe/Stockholm:20211126T093000
DTSTAMP:20260527T140900
CREATED:20211014T115823Z
LAST-MODIFIED:20211014T120713Z
UID:10000465-1637917200-1637919000@www.scilifelab.se
SUMMARY:Clinical Talks: The road towards precision medicine in Sweden
DESCRIPTION:On November 26\, we will host Karolinska Institutet (KI) Professor Richard Rosenquist Brandell. In addition to his academic research and clinical work\, he also co-founded the Genomic Medicine Sweden (GMS) initiative and serves as the Director of GMS. Richard will share his insights on Sweden’s national strategy to implement precision medicine into our healthcare environment and pave the way for the amazing potential the approach has to offer. To benefit from the sustainable advantages of tailored and efficient use of diagnostics and treatment options\, Sweden needs to prepare our society for the legal challenges and infrastructures necessary to support and enable this transformation. \n\n\n\nRead more about clinical talks\n\n\n\nRichard Rosenquist Brandell\, MD\, PhD\, is Professor of Clinical Genetics at Karolinska Institutet\, Senior Physician at Karolinska University Hospital and director of Genomic Medicine Sweden\, a national infrastructure for implementation of precision medicine. He obtained his MD degree in 1996\, and later his PhD in Medicine in 1998\, from Umeå University. In 2000 Richard joined Uppsala University Hospital (“Akademiska Sjukhuset”) and in 2007 became a Professor at the Department of Immunology\, Genetics and Pathology\, Uppsala University. In April 2017\, he relocated to the Karolinska University Hospital as a Senior Physician and Professor. Richard’s work focuses on hematological malignancies and utilizing high-throughput sequencing technologies\, his team has identified novel prognostic and predictive biomarkers that have significantly improved patient risk-stratification.  Dr Rosenquist Brandell is also a member of the Nobel Assembly at Karolinska Institutet. \n\n\n\nGenomic Medicine Sweden (GMS) started as a bottom-up initiative within the national Clinical Genomics Platform (previously named the Diagnostics Development platform) at the Swedish Science for Life Laboratory (SciLifeLab). In 2017 and 2018 discussions with funding agencies\, decision-makers\, healthcare providers\, patient organisations\, universities\, and industry led to the founding of GMS as a national venture. GMS strategic mission is to foster collaboration between healthcare providers\, academia\, patient organizations and industry and realize precision medicine by effectively utilizing the rapidly advancing sequencing technologies to provide the highest standards of genomic testing in routine clinical care throughout Sweden. \n\n\n\nRegistration
URL:https://www.scilifelab.se/event/clinical-talks-the-road-towards-precision-medicine-in-sweden/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2021/09/ClinicalTalks_Season5_twitter_1024.jpg
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211029T090000
DTEND;TZID=Europe/Stockholm:20211029T093000
DTSTAMP:20260527T140900
CREATED:20211014T115257Z
LAST-MODIFIED:20211028T115510Z
UID:10000464-1635498000-1635499800@www.scilifelab.se
SUMMARY:Clinical Talks: Blood-based methods for predicting the day of labor
DESCRIPTION:On October 29\, we will host a dual presentation with Dr. Ina Stelzer and Associate Professor Brice Gaudillière. At the Stanford School of Medicine Clinical Gaudillière laboratory\, Ina and Brice have developed a groundbreaking multi-omics approach to track the maternal metabolome\, proteome and immunome to predict exact labor onset. Estimating the time of delivery is of high clinical importance to minimize pre- and post-term deviations causing complications and suffering with ultimately more streamlined use of medical resources for a sustainable future. \n\n\n\n \n\n\n\nRead more about clinical talks\n\n\n\n\n\n\n\nIna is a molecular biologist and immunologist with an extensive background in pregnancy immunology. She obtained her PhD in Immunology 2017 from the University Medical Center Hamburg-Eppendorf (part of the University of Hamburg). Her work then focused on the immunology of pregnancy and feto-maternal immune crosstalk with a focus on fetal origin of disease development later in life. Ina is currently pursuing her postdoctoral research at Stanford University in the Gaudillière laboratory. Building on her expertise in preclinical (mouse) models of pregnancy and translational systems immunology\, her research leverages state-of-the-art single cell proteomic techniques (suspension and imaging mass cytometry) to study feto-maternal immune adaptations in healthy and pathological pregnancies with the goal to improving the health of mothers and their children. Her current K99/R00-funded work investigates the neuro-immune axis in normal pregnancy and the pathogenesis of pregnancy complications. While at Stanford during 2021\, Ina also recently completed the prestigious Stanford University Graduate School of Business organized Stanford Ignite certificate program. \n\n\n\n\n\n\n\nAssociate Professor Brice Gaudillière initially studied Engineering at Ecole Polytechnique in Paris before completing an MD-PhD degree from the Harvard-MIT Health Sciences and Technology program in 2009. During his postdoctoral fellowship at Stanford University in Dr. Garry Nolan’s laboratory\, he developed and standardized a pipeline to implement CyTOF in clinical studies. Brice is also a Board Certified Anesthesiologist and works clinically in the operating room 25% of his time. \n\n\n\nGaudilliere’s research group combines high parameter mass cytometry (suspension and imaging mass cytometry) with other proteomics approaches to study how the human immune system responds and adapts to physiological or pathological stressors. Ongoing studies in the Gaudilliere lab focus on several clinical scenarios including\, 1) surgical recovery and traumatic injury (NIGMS R35\, Stanford ITI\, Anesthesia department FIDL\, 2) pregnancy and preterm birth (Doris Duke Foundation\, Stanford Prematurity Center grants from the Bill and Melinda Gates and the March of Dimes Foundation\, 3) Host immune response to COVID-19 infection (FAST grant)\, 4) neurocognitive recovery after stroke (PHIND grant). \n\n\n\nregister here
URL:https://www.scilifelab.se/event/blood-based-methods-for-predicting-the-day-of-labor/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2021/09/ClinicalTalks_Season5_twitter_1024.jpg
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
END:VCALENDAR